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Defining and negotiating the relations between academic providers of medical 
education programs and pharmaceutical industry sponsors formed the focus of the 
second meeting of the Jefferson Industry Advisory Council (JIAC) on July 17, 2003.  
Thirty persons attended, fourteen representing pharmaceutical companies and 
sixteen Jefferson physicians, department heads and administrators.  
 
Recent concerns about the encroachments of commerce into medical professionalism 
have made the questions raised at the JIAC meeting urgent. On September 10, 
2002, the Accreditation Council for Graduate Medical Education (ACGME) released a 
draft of new standards relating to the sponsorship of continuing medical education 
(CME) activities by drug companies. The draft states that “the conflict of values 
between the professional ethics of the physician and the business ethics of industry 
is impossible to ignore.”1, An even stronger position was taken by Dr. Arnold Relman 
of Harvard Medical School, who charged in a May 14, 2003, commentary in the 
Journal of the American Medical Association that “the growing intrusion of the 
pharmaceutical companies into medical education” is an issue of the first importance 
to the medical profession and that there should be “no equivocation” about the 
necessity for separating professional CME from the marketing and promotional 
campaigns of drug companies.2
Recent events have only underscored these words. A June 29, 2003, article in The 
Boston Globe (“Hospital, drug firm relations probed”) described how federal 
investigators are probing pharmaceutical marketing practices, doctor-drug sales 
representative interactions, and possible anti-kickback violations.3 Subpoenas have 
been served to many top academic medical centers in Boston and elsewhere, 
although so far only Tufts-New England Medical Center has confirmed that it was 
investigated last fall in connection with an AstraZeneca sales promotion.  
 
More sensationally, in July of this year, Dateline NBC featured an interview with 
David Franklin, former Warner-Lambert sales representative and medical science 
liaison officer, who blew the whistle on illegal encouragement of off-label use of 
medications.4 Franklin testified that he had been involved in deceptive sales 
practices, one of which involved introducing himself as Dr. Franklin and allowing the 
physician to assume he was a medical doctor rather than a PhD.  
 
Given these developments, the JIAC felt it was important to begin formulating 
standards that would apply to the medical/academic community at Jefferson in its 
interactions with pharmaceutical companies. After an opening welcome by Geno J. 
Merli, MD, the Ludwig Kind Professor of Medicine and Senior Associate Dean of 
Continuing Medical Education, Dr. David Nash, Director of the Office of Health Policy 
and Clinical Outcomes, spoke on the “Environmental Scan: Industry and Medical 
Education.” Dr. Nash stressed that academia and industry need each other; from 
that mutual need a morally appropriate interaction can be developed, for it is 
important to maintain the benefits of continuing medical education programs. 
Sponsorship by industry for some of these programs is essential.    
 
Dr. Nash thought that excessive sales initiatives by industry and pharmaceutical 
companies in medical education could be considered the medical equivalent of 
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corporate malfeasance of the likes of Enron and others. The recent exposures of such 
practices has meant that “the days of drug company sales reps in hospital rooms” 
are over. Yet, the consensus in the meeting was that a middle ground could be found 
– not by completely banning the presence of pharmaceutical companies in situ, but 
by making clear distinctions between educational and marketing activities.  While 
medical schools must retain all responsibility for the conduct and content of CME 
courses, they might be positioned to offer tailored, academic, evidence-based 
instruction not only to physicians but to industry representatives as well. Implicit in 
the relationship between academic medical centers and industry is the establishment 
of safeguards to ensure compliance with HIPAA regulations in addition to university 
and hospital policies and procedures. It is important that all parties know who is on-
site and why they are there. A central registry for all non-patient related visitors is 
one possibility. 
 
Other highlights of the meeting included a presentation by Jeff Fetterman, President, 
ParagonRx, on “Applying Principles of Adult Education to CME,” and presentations by 
Jefferson faculty members Howard Greenberg, MD, Medical Director of the Clinical 
Research Unit; Edward Tawyea, PhD, Director of Academic Information Services and 
Research; Neil Goldfarb, Director of Research, Office of Health Policy and Clinical 
Outcomes; and Richard Wender, MD, Alumni Professor and Chair, Department of 
Family Medicine. All presentations provided current examples of creative and 
innovative approaches to learning in the academic/industry partnership.  
 
JIAC members agreed that innovation is the key to adaptation.  Not only is the future 
of CME at stake, but pharmaceutical company leaders must realize that their 
continued business depends in a fundamental way upon public confidence in doctors 
and the medical practice. The separation of marketing from educational functions will 
necessitate new ways of evaluating pharmaceutical company return on investment. 
As one committee member put it,  “We can’t even use the term “return on 
investment” anymore.”  The current term, he said, is “commitment instrument.” A 
return on investment points to a purely financial interest, whereas a commitment 
instrument implies a commitment to the educational and research basis of all 
developed products.  
 
Participants of the Jefferson Industry Advisory Council meeting recognized the 
challenges facing the academic/industry partnership, but there was also the sense 
that these challenges could be turned into opportunities. Both sides of the 
partnership showed the ability to face facts combined with willingness to discuss 
guidelines for new and creative ways of working together. It was an important step 
in defining what the respective roles of academia and industry are to be, and more 
discussions are expected to follow when JIAC meets again in 2004.  Please address 
questions and comments to Jeanne Cole, MS, Director, Jefferson Medical College 
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